The Female Health Company (FHC) manufactures, markets and sells the FC2 female condom. FC2 is approved by the United States Food and Drug Administration (FDA) that provides dual protection against unintended pregnancy and sexually transmitted infections (STIs), including Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). Prior to October 2009, the Company completed the transition from its first generation product, FC1, to its second generation product, FC2, and production of FC1 ceased. Although FC1 production has ceased, the Company retains its ownership of certain worldwide rights to FC1, as well as various patents, regulatory approvals and other intellectual property related to FC1. From introduction its in March 2007, through September 30, 2011, approximately 109 million FC2 female condoms have been distributed in 120 countries and it is sold directly to consumers in 14 countries.